dpp-4 inhibitor and glp-1 receptor agonist combination not recommended ada Development of a treatment selection algorithm for SGLT2 therapies in people with type 2 diabetes: a retrospective cohort study The effect of DPP-4 inhibitors,

Diabetologia 66 , 18461858 (2023)

Ectopic, hepatic GLP-1R agonism enhances the weight loss efficacy of GLP-1 analogues

Recently, we highlighted two small molecule leaders in the GLP-1R agonism space, orforglipron and danuglipron

doi: 10.1530/EC-17-0294 228 ZhangDMaMLiuY

Theres also this recent headline: Which is a touchy subject and I dont want to settle the European regulators investigation (notoriously not overly sensitive about things), but Id venture to say that the psychological impact of obesity and the psychiatric side effects associated with changing body type including dysmorphia and eating disorders probably indicate that this is not a side effect of the drug but rather a side effect of the primary effect of the drug, in a small subset of patients

Vance V., Mourtzakis M., McCargar L., and Hanning R., Weight Gain in Breast Cancer Survivors: Prevalence, Pattern and Health Consequences, Obesity Reviews 12 (2011): 282294